On 4 February 2026, IAPO delivered a statement on Agenda item 12 on substandard and falsified medical products at the 158th session of the WHO Executive Board on behalf of the Fight the Fakes Alliance, of which IFPMA is a member. The International Alliance of Patients’ Organizations, on behalf of the Fight the Fakes Alliance,...
Read moreOn 3 February 2026, IFPMA delivered a statement on Agenda item 9: Co-creating the Global Action Plan for rare diseases at the 158th session of the WHO Executive Board. IFPMA commends Member States and the WHO for implementing the 2025 WHA Resolution on Rare Diseases and strongly supports the prompt initiation of a Global Action...
Read moreOn 2 February 2026, PATH delivered a joint constituency statement on Agenda itea 6: Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases at the 158th session of the WHO Executive Board. Sustainable and responsible financing—powered by multisectoral collaboration—is key to meet the...
Read moreOn 1st December 2025 in Geneva, IFPMA delivered a statement at the fourth meeting of the open-ended Intergovernmental Working Group (IGWG 4) on the WHO Pandemic Agreement.
Read moreOn 20 November 2025, IFPMA submitted a statement on technology transfer at the WIPO Committee on IP and Development (CDIP 35) in Geneva. Technology transfer in the pharmaceutical sector is a complex and resource-intensive process. It requires significant technical expertise, time, and investment, as well as a robust, stable, and predictable intellectual property framework, which...
Read more12 NOVEMBER 2025, Berlin – The Biopharmaceutical CEOs Roundtable (BCR), a global policy platform representing the world’s leading biopharmaceutical companies, convened last week in Berlin to discuss how pharmaceutical innovation can drive better health outcomes, strengthen economies, and enhance global health security. The BCR delegation also met with Federal Chancellor Merz, along with key members...
Read moreOn 5 November 2025, IFPMA delivered a statement on technology transfer at the WIPO Standing Committee on Patents (SCP 37) in Geneva. Technology transfer in the pharmaceutical sector is a complex and resource-intensive process. It requires significant technical expertise, time, and investment, as well as a robust, stable, and predictable intellectual property framework, which is...
Read moreOn 4 November 2025, IFPMA delivered a statement on patents and health at the WIPO Standing Committee on Patents (SCP 37) in Geneva. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the global research-based biopharmaceutical industry. We appreciate the opportunity to address the Committee on patents and health. Intellectual property is fundamental to...
Read moreOn 3 November 2025 in Geneva, IFPMA delivered a statement at at the tnird meeting of the open-ended Intergovernmental Working Group (IGWG 3) on the WHO Pandemic Agreement.
Read moreOn 30 October 2025 at the 75th WHO Regional Committee for Europe, IFPMA, together with European member association EFPIA, submitted a statement on the Action Plan for the Prevention and Control of Noncommunicable Diseases in the WHO European Region 2016-2025. This statement is delivered on behalf of IFPMA and its European member organization EFPIA. We...
Read moreOn 21 October 2025 in Nadi, Fiji, IFPMA delivered a statement at the 76th Session of the WHO Regional Committee for the Western Pacific on “Implementing the International Health Regulations (2005) amendments.” We commend the Western Pacific Region for its engagement to develop priority actions for countries and areas in the region to utilize the...
Read moreOn 14 October 2025 in Colombo, Sri Lanka, IFPMA delivered a statement on primary health care (PHC) and universal health coverage (UHC) at the 78th Session of the WHO Regional Committee for South-East Asia. IFPMA welcomes the agenda items on PHC and UHC. Unlocking investment in primary care is critical if we are to build...
Read more